Stocktoria
Kyverna Therapeutics, Inc. KYTX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2024-02-08
Chart by TradingView
1/9
Piotroski F — financial health
0.87
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Financials | |||
| Operating income | -$169.8M | -$142.6M | -$62.4M |
| Net income | -$161.3M | -$127.5M | -$60.4M |
| Operating cash flow | -$153.7M | -$114.2M | -$52.4M |
| Free cash flow | -$153.7M | -$116.5M | -$53.0M |
| Total assets | $293.8M | $304.6M | $75.2M |
| Total liabilities | $61.5M | $38.1M | $26.0M |
| Shareholders' equity | $232.3M | $266.6M | -$13.1M |
| Ratios | |||
| Return on assets | -54.9% | -41.8% | -80.3% |
| Return on equity | -69.4% | -47.8% | 459.4% |
| Current ratio | 7.75 | 8.61 | 3.05 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 367,492 | $3.2M |
| Point72 Asset Management, L.P. | 222,929 | $1.9M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 0.87 (distress)
- Working capital / assets 0.839
- Retained earnings / assets -1.446
- EBIT / assets -0.578
- Equity / liabilities 3.774
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001994702 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.